SINOMAB BIO-B (03681) announced that on March 12, 2026, Hainan Cellomics and Shenzhen Cellomics Biotech Co., Ltd. (collectively referred to as the "Tenant"), a wholly-owned subsidiary of the company, entered into an agreement with Haikou Pharmaceutical to terminate the existing lease agreement, effective from March 12, 2026. The Tenant is required to vacate the premises and remove any remaining items within 15 days from the effective date.

The decision follows the company's strategy to optimize resource allocation and enhance operational flexibility. After extensive negotiations, the parties mutually agreed to terminate the lease agreement ahead of schedule.

The Board of Directors considers the termination to be a reasonable and pragmatic step in the company's transition towards a lighter asset manufacturing model. Candidate drugs for preclinical studies and clinical trials, previously manufactured at the production base under the lease agreement, will now be outsourced to Contract Development and Manufacturing Organizations (CDMOs). This shift is expected to provide significant cost advantages for the Group.

The Board believes the termination will not have any material adverse effect on the Group's financial condition or operations and is in the best interests of the company and its shareholders.